PepGen (NASDAQ:PEPG – Get Free Report) and Femasys (NASDAQ:FEMY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Profitability
This table compares PepGen and Femasys’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PepGen | N/A | -75.73% | -60.42% |
| Femasys | -812.74% | -534.94% | -116.29% |
Valuation and Earnings
This table compares PepGen and Femasys”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PepGen | N/A | N/A | -$89.65 million | ($2.41) | -0.66 |
| Femasys | $2.29 million | 10.51 | -$18.63 million | ($0.50) | -0.80 |
Femasys has higher revenue and earnings than PepGen. Femasys is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
PepGen has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.28, suggesting that its share price is 328% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for PepGen and Femasys, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PepGen | 1 | 0 | 5 | 0 | 2.67 |
| Femasys | 1 | 0 | 4 | 0 | 2.60 |
PepGen presently has a consensus target price of $11.80, suggesting a potential upside of 642.14%. Femasys has a consensus target price of $5.50, suggesting a potential upside of 1,279.48%. Given Femasys’ higher probable upside, analysts plainly believe Femasys is more favorable than PepGen.
Institutional and Insider Ownership
58.0% of PepGen shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 5.2% of PepGen shares are owned by insiders. Comparatively, 11.5% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
PepGen beats Femasys on 7 of the 13 factors compared between the two stocks.
About PepGen
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.
